127 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35050813 | Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. | 2022 Feb | 1 |
2 | 35253964 | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension. | 2022 Apr | 1 |
3 | 35343479 | [Sacubitril/valsartan in oncologic patients with cardiotoxicity: another weapon in our pharmacological armory?] | 2022 Apr | 1 |
4 | 35469709 | Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. | 2022 Apr 22 | 2 |
5 | 33148948 | TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. | 2021 Jan | 1 |
6 | 33189632 | Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. | 2021 Feb | 1 |
7 | 33422508 | Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening! | 2021 Mar 5 | 1 |
8 | 33459776 | Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. | 2021 Feb 11 | 1 |
9 | 33732669 | Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy. | 2021 | 1 |
10 | 33808232 | Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF. | 2021 Mar 30 | 1 |
11 | 33822031 | Renal protection in chronic heart failure: focus on sacubitril/valsartan. | 2021 Sep 21 | 1 |
12 | 33989294 | Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction? | 2021 | 1 |
13 | 34173810 | Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan. | 2021 Sep 1 | 1 |
14 | 34216577 | Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. | 2021 Sep 15 | 1 |
15 | 34273070 | Current and emerging drug targets in heart failure treatment. | 2021 Jul 17 | 1 |
16 | 34612065 | Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. | 2021 Oct 19 | 1 |
17 | 34703936 | Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure. | 2021 Oct 8 | 1 |
18 | 34859070 | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. | 2021 | 1 |
19 | 30776953 | Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia. | 2020 Oct | 1 |
20 | 30991886 | Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. | 2020 Aug | 1 |
21 | 31028383 | Chronic kidney disease, heart failure and neprilysin inhibition. | 2020 Apr 1 | 1 |
22 | 31392960 | Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. | 2020 Jan | 1 |
23 | 32319309 | ARNI in cardiovascular disease: current evidence and future perspectives. | 2020 Sep | 1 |
24 | 32336521 | When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry. | 2020 Mar | 1 |
25 | 32348960 | Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. | 2020 May | 1 |
26 | 32352509 | Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan). | 2020 Jul 1 | 1 |
27 | 32370992 | Response to the Letter to the Editor "When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry". | 2020 Mar | 1 |
28 | 32490351 | Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. | 2020 | 1 |
29 | 32648251 | Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure. | 2020 | 1 |
30 | 32653447 | Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. | 2020 Oct | 1 |
31 | 32710603 | Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure. | 2020 Oct | 1 |
32 | 32744827 | Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration? | 2020 Sep | 1 |
33 | 32848403 | Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data. | 2020 | 1 |
34 | 32987038 | Neprilysin expression and functions in development, ageing and disease. | 2020 Dec | 2 |
35 | 32995716 | Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. | 2020 Sep | 1 |
36 | 33004114 | Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. | 2020 Oct | 1 |
37 | 33032741 | Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. | 2020 Oct 13 | 1 |
38 | 33203141 | The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. | 2020 Nov 15 | 1 |
39 | 33224383 | Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. | 2020 Dec | 1 |
40 | 33489085 | Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. | 2020 | 1 |
41 | 33727901 | The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. | 2020 Nov | 1 |
42 | 29450561 | Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study. | 2019 Sep | 2 |
43 | 29635392 | Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients? | 2019 Jan 1 | 1 |
44 | 29891240 | Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. | 2019 Apr 15 | 1 |
45 | 29926350 | Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. | 2019 Feb | 1 |
46 | 30420146 | Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. | 2019 Apr 15 | 1 |
47 | 30520545 | Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. | 2019 May | 4 |
48 | 30679005 | Sacubitril/valsartan: A practical guide. | 2019 May | 1 |
49 | 30712431 | Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. | 2019 Feb 5 | 1 |
50 | 30895809 | Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35. | 2019 May | 1 |